298 related articles for article (PubMed ID: 15068398)
1. Gefitinib, a novel, orally administered agent for the treatment of cancer.
Ranson M; Wardell S
J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
3. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Wolf M; Swaisland H; Averbuch S
Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
Reck M; Gatzemeier U
Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
[TBL] [Abstract][Full Text] [Related]
8. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Vansteenkiste J
Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib.
Culy CR; Faulds D
Drugs; 2002; 62(15):2237-48; discussion 2249-50. PubMed ID: 12381224
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib for advanced or metastatic non-small cell lung cancer.
Perras C
Issues Emerg Health Technol; 2004 Apr; (55):1-4. PubMed ID: 15085875
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Miller VA; Johnson DH; Krug LM; Pizzo B; Tyson L; Perez W; Krozely P; Sandler A; Carbone D; Heelan RT; Kris MG; Smith R; Ochs J
J Clin Oncol; 2003 Jun; 21(11):2094-100. PubMed ID: 12775734
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Prescrire Int; 2004 Oct; 13(73):168-70. PubMed ID: 15499696
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib therapy for advanced non-small-cell lung cancer.
Liu CY; Seen S
Ann Pharmacother; 2003 Nov; 37(11):1644-53. PubMed ID: 14565788
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of gefitinib in patients receiving treatment in everyday clinical practice.
van Zandwijk N
Br J Cancer; 2003 Dec; 89 Suppl 2(Suppl 2):S9-14. PubMed ID: 14661047
[TBL] [Abstract][Full Text] [Related]
17. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
[TBL] [Abstract][Full Text] [Related]
18. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Reck M; Gatzemeier U
Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
[TBL] [Abstract][Full Text] [Related]
19. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
20. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Forsythe B; Faulkner K
Drug Saf; 2004; 27(14):1081-92. PubMed ID: 15554744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
